Thessaloniki, 18-20/4/2019

IASIS PHARMA participated in the 19th Panhellenic Conference for Hypertension. The event took place in 18-20 April 2019, at Makedonia Palace Hotel, Thessaloniki, under the auspices of the Greek Society of Hypertension (E.E.Y).

At IASIS PHARMA stand, HCPs were informed about the range ofhigh quality pharmaceutical products that IASIS PHARMA offers in the CVP field.

Rami-Amlo® is a new, original product of a fixed-dose combination (FDC), that belongs to the pharmaceutical categories of angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers. Rami-Amlo® hard capsule comes in the following Ramipril/Amlodipine strengths: 5mg/5mg, 5mg/10mg, 10mg/5mg, also in the unique FDC of Ramipril + Amlodipine 10mg/10 mg strength, thus fully covering all therapeutic needs.

IASIS PHARMA presented MAG-IASIS®, a combination of 1193.57 mg magnesium citrate and 667.56 mg magnesium aspartate dihydrate, equivalent to 243 mg of Magnesium in effervescent form, Pharma Grade. MAG-IASIS® is produced in Greece, at IASIS PHARMA state-of-the-art effervescent tablets manufacturing facility.

IASIS PHARMA launched Glucofree® & Glucoplus®, both having Metformin hydrochloride as their active ingredient, at 850mg and 1000mg strength respectively. Metformin is the 1st therapeutic step in every Diabetes Mellitus Type II treatment algorythm.
Glucofree® is available in 850mg, 60 fc tablets package, and Glucoplus® is produced in 1000mg, 30 fc tablets package.